Cellectis Success With Off-The-Shelf CAR-T Threatens Kite, Juno, Novartis
This article was originally published in Scrip
Executive Summary
An unexpected breakthrough announced by Cellectis for its experimental off-the-shelf CAR-T therapy has raised the possibility that much-hyped therapies using a patient's own cells, under development at Kite, Juno and Novartis, may become commercially obsolete before they even reach the market.
You may also be interested in...
Cellectis Files IND For Talen-Edited 'Off-The-Shelf' CAR-T Candidate
Cellectis has filed an IND for US testing of its TALEN-edited CAR-T immune-oncology therapy UCART123. Servier has already begun clinical testing with Cellectis' lead program, UCART19, in Europe. The product is licensed to Pfizer in the US.
Deal Watch: Roche Aborts But Regeneron, Amgen and Pfizer Sign Up
Deal activity over the past seven days sees Roche knock back Inovio a second time, Regeneron plan for its future via an alliance with Adicet Bio, Amgen supplement its preclinical pipeline with a candidate from Advaxis, and Pfizer shore up its gene therapy ambitions with an acquisition.
The Impact Of COVID-19 On Clinical Trials
Clinical trials for therapeutic areas aside from COVID-19 are experiencing disruptions and delays as social distancing measures and travel restrictions are implemented across the world.